Insulet Corporation with ticker code (PODD) now have 16 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 360 and 208 suggesting an average Analsyt target price of $281.56. Given that the stocks previous close was at $170.98 and the analysts are correct then we can expect a percentage increase in value of 64.7%. Also worth taking note is the 50 day moving average now sits at $228.40 and the 200 day MA is $281.73. The company has a market capitalization of 11.69B. The stock price for the company is currently 167.38 USD
The potential market cap would be $19,244,912,573 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 183.93, revenue per share of 21.06 and a 2.06% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
